Blocking a protein to prevent SARS-CoV-2 infection
Blocking TMPRSS2 expression for prevention of SARS-CoV-2 infection
['FUNDING_R21'] · UNIVERSITY OF GEORGIA · NIH-10449301
This study is looking at whether blocking a certain protein called TMPRSS2 can help stop the SARS-CoV-2 virus from getting into our cells, and it's for anyone interested in new ways to fight COVID-19.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF GEORGIA (nih funded) |
| Locations | 1 site (ATHENS, UNITED STATES) |
| Trial ID | NIH-10449301 on ClinicalTrials.gov |
What this research studies
This research investigates how blocking the expression of a specific protein, TMPRSS2, can prevent the SARS-CoV-2 virus from entering human cells. The approach involves using inhibitors that target androgen receptor signaling, which is known to regulate TMPRSS2 levels. By reducing TMPRSS2 in respiratory epithelial cells, the research aims to stop the virus from activating and infecting these cells. The study will involve both genetic and pharmacological methods to assess the effectiveness of these inhibitors in a laboratory setting.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for SARS-CoV-2 infection, particularly those with underlying health conditions that affect respiratory function.
Not a fit: Patients who are not at risk for SARS-CoV-2 infection or those who have already been vaccinated may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new preventive strategies against SARS-CoV-2 infection, potentially reducing the spread of COVID-19.
How similar studies have performed: Other research has shown promise in targeting TMPRSS2 and androgen receptor signaling as a viable approach to inhibit viral infections, suggesting potential success for this study.
Where this research is happening
ATHENS, UNITED STATES
- UNIVERSITY OF GEORGIA — ATHENS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CAI, HOUJIAN — UNIVERSITY OF GEORGIA
- Study coordinator: CAI, HOUJIAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.